Literature DB >> 15990307

Erysipelas of the upper extremity following locoregional therapy for breast cancer.

Nagi S El Saghir1, Zaher K Otrock, Abdul Rahman N Bizri, Marwan M Uwaydah, Gerard O Oghlakian.   

Abstract

Cellulitis is a well-known complication of lymphedema of the lower extremities. Erysipelas of the upper extremity complicating breast cancer therapy has never been reported in the English-language literature. We describe seven breast cancer patients with erysipelas of the upper extremity. Five had a predisposing injury to the extremity. All patients responded very well to intravenous antibiotics without any sequelae. They had rapid resolution with typical desquamation. No long-term sequelae were seen except for mild increase of lymphedema. Erysipelas should be listed as a rare complication after locoregional therapy for breast cancer. Intravenous penicillin should be used as the initial therapy. Prevention of arm lymphedema and avoidance of any trauma to the arm are important prophylactic measures. Sentinel lymph node biopsy reduces the rate of axillary lymph node dissection and thus should reduce the incidence of lymphedema and erysipelas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990307     DOI: 10.1016/j.breast.2005.02.011

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  3 in total

1.  Regulatory T Cells Mediate Local Immunosuppression in Lymphedema.

Authors:  Gabriela D García Nores; Catherine L Ly; Ira L Savetsky; Raghu P Kataru; Swapna Ghanta; Geoffrey E Hespe; Stanley G Rockson; Babak J Mehrara
Journal:  J Invest Dermatol       Date:  2017-09-20       Impact factor: 8.551

2.  Prevalence and Epidemiological Factors Involved in Cellulitis in Korean Patients With Lymphedema.

Authors:  Sae In Park; Eun Joo Yang; Dong Kyu Kim; Ho Joong Jeong; Ghi Chan Kim; Young-Joo Sim
Journal:  Ann Rehabil Med       Date:  2016-04-25

3.  Analysis of Serum Cytokines and Single-Nucleotide Polymorphisms of SOD1, SOD2, and CAT in Erysipelas Patients.

Authors:  Charles C Emene; Irina E Kravchenko; Gulnaz I Aibatova; Albert A Rizvanov
Journal:  J Immunol Res       Date:  2017-04-23       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.